Claybrook Capital’s Biogen BIIB Stock Holding History

Claybrook Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4	Closed	-$1K	–	153
2018 Q4	$1K	Buy	+4	New	+$1.28K	﹤0.01%	675

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Claybrook Capital's BIIB Position: Q1 2019 in Review

Claybrook Capital sold out of Biogen (BIIB) in Q1 2019, closing a stake of 4 shares — an estimated $1K sold.

Claybrook Capital first reported a position in BIIB in Q4 2018 and held it in 1 quarter. The position peaked at $1K in Q4 2018. 1,084 funds tracked by Wall St. Rank hold BIIB as of Q1 2019.

Claybrook Capital reported no remaining Biogen position as of Q1 2019 after selling out during the quarter.
Claybrook Capital sold 4 Biogen shares in Q1 2019, an estimated $1K.
Claybrook Capital first reported a position in Biogen in Q4 2018 and held it in 1 quarter.
Claybrook Capital's Biogen position peaked at $1K in Q4 2018.
1,084 funds tracked by Wall St. Rank held Biogen as of Q1 2019.

Based on Claybrook Capital's 13F filing for Q1 2019, filed 15 May 2019.